Equels Thomas K, the CEO and President of AIM ImmunoTech Inc., has reported a stock transaction involving 38,000 shares of the company. This transaction, filed on November 17, 2026, is significant as it underscores the ongoing activity of key executives in managing their stock holdings.

AIM ImmunoTech Inc. operates in the biological products sector, focusing on developing therapeutic solutions. The company is incorporated in Delaware and has its business address in Ocala, Florida.

According to the filing, on November 16, 2026, Equels acquired 38,000 shares at a price of $0.135 per share. Following this transaction, he now owns a total of 366,095 shares directly. The filing indicates that Equels is both a director and an officer of the company, holding the title of CEO & President.

This update may impact stakeholders, including investors and employees, as it reflects the confidence of leadership in the company's future. The filing does not specify what happens next.

Transaction Details

The transaction was classified under the code 'P', indicating that it was a purchase of shares. Equels' acquisition of 38,000 shares at a price of $0.135 per share demonstrates a direct investment in AIM ImmunoTech Inc.'s common stock. Following this transaction, his total ownership increased to 366,095 shares, all of which are held directly.

Company Information

AIM ImmunoTech Inc. is categorized under the Standard Industrial Classification of Biological Products (No Diagnostic Substances) [2836]. The company is incorporated in Delaware and has a fiscal year that ends on December 31. The business address is located at 2117 SW Highway 484, Ocala, Florida, 32801, with a contact number of 352-448-7797.

This filing does not include information on the reasons behind the stock purchase or any future plans for the shares acquired.